Altered TCR signaling in anergy

无能状态下 TCR 信号传导的改变

基本信息

  • 批准号:
    10750486
  • 负责人:
  • 金额:
    $ 24.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-07-06 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Abstract T cell anergy is a cell-intrinsic program of non-responsiveness to self-antigens, and is an important component of peripheral tolerance. As the induction and maintenance of anergy is critical to preventing breakdown of tolerance and initiation of autoimmunity, it is important to understand the mechanisms and molecules that regulate anergy. Initially, T cell anergy was induced by TCR stimulation in the absence of costimulation and a variety of stimuli have been used in vitro to induce anergy. This early work demonstrated the critical importance of activation of the Ras/Map kinase pathway upon TCR/CD28 stimulation for T cell activation, IL-2 production and proliferation. However, the mechanism is not clear as to how the Ras/Map kinase pathway is downregulated in anergic T cells. Recently, endogenously anergic T cells in WT mice have been identified and are characterized by high expression of CD73 and FR4. We have found that these naturally anergic FR4+CD73+ CD4+ T cells in vivo from WT mice express lower levels of Runx1 protein as compared to other CD4+ T cell subsets. TCR/CD28-induced activation of CD4+ T cells with conditional deletion of Runx1 resulted in lower IL-2 expression and reduced proliferation as compared to activation of WT CD4+ T cells. In addition, there was a higher frequency of naturally anergic FR4+CD73+ CD4+ T cells in CD4- cre Runx1 conditional knockout (cKO) mice or tamoxifen-treated ER-cre Runx1 cKO mice in mixed bone marrow chimeras. Thus, deletion of Runx1 in mature CD4+ T cells predisposes them to the development of T cell anergy. To understand the mechanism(s) responsible for hypo-responsiveness of Runx1-deficient T cells upon TCR/CD28 stimulation, RNAseq analysis was performed on WT and Runx1-deficient CD4+ T cells. Runx1-deficient CD4+ T cells upregulated expression of Dab2IP, an adaptor molecule that has been shown in non-hematopoietic cells to be a negative regulator of Ras signaling. Dab2IP contains a Ras-GAP domain, which leads to the inactivation of Ras through accelerating hydrolysis of GTP to GDP. To determine whether increased Dab2IP expression could inhibit T cell activation and promote anergy induction, we generated a novel cre-dependent, dox-regulatable Dab2IP transgenic mouse. Our initial results demonstrate that similar to CD4+ T cells conditionally deleted for Runx1, Dab2IP Tg CD4+ T cells have increased frequencies of naturally anergic FR4+CD73+ CD4+ T cells in their memory cell pool. Our hypothesis is that increased expression of Dab2IP interferes with normal TCR/CD28 signaling, preventing T cell activation, and predisposing T cells to the development of anergy.
摘要 T细胞无反应性是一种对自身抗原无反应性的细胞内在程序,并且是T细胞免疫的重要机制。 外围公差的组成部分。由于无反应性的诱导和维持对于预防 耐受性的破坏和自身免疫的启动,重要的是要了解机制, 调节无反应性的分子最初,T细胞无反应性是由TCR刺激诱导的, 共刺激和多种刺激物已在体外用于诱导无反应性。早期的研究表明, Ras/Map激酶通路在TCR/CD 28刺激T细胞后激活的重要性 活化、IL-2产生和增殖。然而,该机制并不清楚Ras/Map 激酶途径在无反应性T细胞中下调。最近,WT小鼠中的内源性无反应性T细胞 已被鉴定并以CD 73和FR 4的高表达为特征。我们发现, 来自WT小鼠的体内天然无反应性FR 4 + CD 73 + CD 4 + T细胞表达较低水平的Runx 1蛋白, 与其他CD 4 + T细胞亚群相比。TCR/CD 28诱导的条件性CD 4 + T细胞活化 与WT激活相比,Runx 1的缺失导致IL-2表达降低和增殖减少。 CD 4 + T淋巴细胞。此外,在CD 4-T细胞中,天然无反应性FR 4 + CD 73 + CD 4 + T细胞的频率更高。 cre Runx 1条件性敲除(cKO)小鼠或他莫昔芬处理的ER-cre Runx 1 cKO小鼠混合骨 骨髓嵌合体因此,在成熟的CD 4 + T细胞中Runx 1的缺失使它们倾向于T细胞的发展。 细胞无能了解Runx 1缺陷型T细胞低反应性的机制 在TCR/CD 28刺激后,对WT和Runx 1缺陷型CD 4 + T细胞进行RNAseq分析。 Runx 1缺陷型CD 4 + T细胞上调Dab 2 IP的表达,Dab 2 IP是一种衔接分子, 非造血细胞是Ras信号传导的负调节因子。Dab 2 IP含有Ras-GAP结构域, 其通过加速GTP水解为GDP而导致Ras失活。以确定是否 增加Dab 2 IP表达可以抑制T细胞活化并促进无反应性诱导,我们产生了一种新的免疫抑制剂。 新型cre依赖性dox可调控的Dab 2 IP转基因小鼠。我们的初步结果表明,类似的 对于Runx 1条件性缺失的CD 4 + T细胞,Dab 2 IP Tg CD 4 + T细胞具有增加的 在它们的记忆细胞库中天然无反应性的FR 4 + CD 73 + CD 4 + T细胞。我们的假设是 Dab 2 IP的表达干扰正常TCR/CD 28信号传导,阻止T细胞活化,和 使T细胞倾向于无反应性的发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Virginia Smith Shapiro其他文献

Nuclear factor of activated T cells and AP-1 are insufficient for IL-2 promoter activation: requirement for CD28 up-regulation of RE/AP.
激活的 T 细胞和 AP-1 的核因子不足以激活 IL-2 启动子:RE/AP 上调 CD28 的必要条件。
  • DOI:
  • 发表时间:
    1998
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Virginia Smith Shapiro;M. Mollenauer;Arthur Weiss
  • 通讯作者:
    Arthur Weiss
The nutrient-sensing Rag-GTPase complex in B cells controls humoral immunity via TFEB/TFE3-dependent mitochondrial fitness
B 细胞中的营养感应 Rag-GTP 酶复合物通过依赖 TFEB/TFE3 的线粒体适应性来控制体液免疫
  • DOI:
    10.1038/s41467-024-54344-5
  • 发表时间:
    2024-11-23
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Xingxing Zhu;Yue Wu;Yanfeng Li;Xian Zhou;Jens O. Watzlawik;Yin Maggie Chen;Ariel L. Raybuck;Daniel D. Billadeau;Virginia Smith Shapiro;Wolfdieter Springer;Jie Sun;Mark R. Boothby;Hu Zeng
  • 通讯作者:
    Hu Zeng

Virginia Smith Shapiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Virginia Smith Shapiro', 18)}}的其他基金

Training Program in Immunology
免疫学培训计划
  • 批准号:
    10493678
  • 财政年份:
    2022
  • 资助金额:
    $ 24.21万
  • 项目类别:
Training Program in Immunology
免疫学培训计划
  • 批准号:
    10650170
  • 财政年份:
    2022
  • 资助金额:
    $ 24.21万
  • 项目类别:
Regulation of B cell development by ABCB7
ABCB7 对 B 细胞发育的调节
  • 批准号:
    10374116
  • 财政年份:
    2021
  • 资助金额:
    $ 24.21万
  • 项目类别:
Regulation of gene expression by HDAC3
HDAC3 对基因表达的调节
  • 批准号:
    10455700
  • 财政年份:
    2020
  • 资助金额:
    $ 24.21万
  • 项目类别:
Regulation of gene expression by HDAC3
HDAC3 对基因表达的调节
  • 批准号:
    10225415
  • 财政年份:
    2020
  • 资助金额:
    $ 24.21万
  • 项目类别:
Regulation of gene expression by HDAC3
HDAC3 对基因表达的调节
  • 批准号:
    10667604
  • 财政年份:
    2020
  • 资助金额:
    $ 24.21万
  • 项目类别:
ST8Sia6 expression on tumors inhibits the immune response
肿瘤上 ST8Sia6 的表达抑制免疫反应
  • 批准号:
    10308083
  • 财政年份:
    2019
  • 资助金额:
    $ 24.21万
  • 项目类别:
ST8Sia6 expression on tumors inhibits the immune response
肿瘤上 ST8Sia6 的表达抑制免疫反应
  • 批准号:
    10529298
  • 财政年份:
    2019
  • 资助金额:
    $ 24.21万
  • 项目类别:
ST8Sia6 expression on tumors inhibits the immune response
肿瘤上 ST8Sia6 的表达抑制免疫反应
  • 批准号:
    9913027
  • 财政年份:
    2019
  • 资助金额:
    $ 24.21万
  • 项目类别:
ST8Sia6 expression on tumors inhibits the immune response
肿瘤上 ST8Sia6 的表达抑制免疫反应
  • 批准号:
    10054986
  • 财政年份:
    2019
  • 资助金额:
    $ 24.21万
  • 项目类别:

相似海外基金

Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens
针对 1 型糖尿病自身抗原的工程化 TCR-Treg 细胞疗法
  • 批准号:
    10764143
  • 财政年份:
    2023
  • 资助金额:
    $ 24.21万
  • 项目类别:
Study of identification for autoantigens in a mouse model of pituitary dysfunction induced by CTLA-4 or PD-1 blockade
CTLA-4或PD-1阻断诱导的垂体功能障碍小鼠模型中自身抗原的鉴定研究
  • 批准号:
    22K08648
  • 财政年份:
    2022
  • 资助金额:
    $ 24.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens
针对 1 型糖尿病自身抗原的工程化 TCR-Treg 细胞疗法
  • 批准号:
    10545634
  • 财政年份:
    2022
  • 资助金额:
    $ 24.21万
  • 项目类别:
identification of autoantigens of autoimmune pancreatitis
自身免疫性胰腺炎自身抗原的鉴定
  • 批准号:
    21H02901
  • 财政年份:
    2021
  • 资助金额:
    $ 24.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Genetic Basis of Variable Expression of Glycan Xeno-Autoantigens by Cattle
牛聚糖异种自身抗原变异表达的遗传基础
  • 批准号:
    DP200103734
  • 财政年份:
    2020
  • 资助金额:
    $ 24.21万
  • 项目类别:
    Discovery Projects
The study to identify novel pathogenesis and autoantigens in patients with membranous nephropathy
确定膜性肾病患者新发病机制和自身抗原的研究
  • 批准号:
    19K08694
  • 财政年份:
    2019
  • 资助金额:
    $ 24.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Project 3-Proteomic Analysis of Explanted Livers with characterization of Autoantigens
项目 3 - 外植肝脏的蛋白质组学分析及自身抗原的表征
  • 批准号:
    10356015
  • 财政年份:
    2019
  • 资助金额:
    $ 24.21万
  • 项目类别:
Project 3-Proteomic Analysis of Explanted Livers with characterization of Autoantigens
项目 3 - 外植肝脏的蛋白质组学分析及自身抗原的表征
  • 批准号:
    10093988
  • 财政年份:
    2019
  • 资助金额:
    $ 24.21万
  • 项目类别:
Project 3-Proteomic Analysis of Explanted Livers with characterization of Autoantigens
项目 3 - 外植肝脏的蛋白质组学分析及自身抗原的表征
  • 批准号:
    10560561
  • 财政年份:
    2019
  • 资助金额:
    $ 24.21万
  • 项目类别:
Identification of autoantigens presented by specific HLA class I alleles in aplastic anemia
再生障碍性贫血中特定 HLA I 类等位基因呈现的自身抗原的鉴定
  • 批准号:
    19H03686
  • 财政年份:
    2019
  • 资助金额:
    $ 24.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了